Best Practices and Research Advances in Thoracic Oncology: A Regional Series SE Asia Course 3: Driver Alterations in Lung Cancer-Molecular Profiling in the Region: Opportunities & Challenges

Molecular Profiling in the Region: Opportunities & Challenges

Video Transcription

Video Summary

Rina Hui, from the University of Hong Kong, emphasizes the significance of molecular profiling in tackling high cancer rates in Asia, where over 60% of lung cancer cases are diagnosed. She highlights how identifying genetic mutations, such as EGFR and ALK, has revolutionized non-small cell lung cancer treatments. Various targeted therapies, including Osimertinib and Alatinib, have significantly extended survival rates, with 60% of metastatic ALK-positive patients now living beyond five years. However, Hui points out challenges like cost and access to molecular testing in low-income Asian countries. Disparities exist in biomarker testing, with lower-income regions showing lower testing rates and starting treatments before biomarker results. Molecular tumor boards, integrating expertise from various fields, are proposed as essential for optimizing treatments and overcoming healthcare disparities. Emphasizing Asia's unique genetic profiles, Hui calls for improved access to molecular testing and targeted therapies to improve patient outcomes.

Keywords

molecular profiling

lung cancer

targeted therapies

biomarker testing

healthcare disparities